GlassScriptPhysician profile
Quinten Black
NPI 1578558474
$3,786.67
in general payments reported to CMS, 2019-2025
49 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 87% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $625 · 2021: $162 · 2023: $91.49 · 2024: $68.34 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $417.37 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $348.45 | 2019-2025 | Keytruda |
| Amgen INC. | $318.95 | 2019-2021 | |
| Celgene Corporation | $239.10 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.90 | 2019-2025 | |
| Daiichi Sankyo INC. | $179.09 | 2019-2025 | Enhertu |
| Tempus Ai, INC | $126.17 | 2025 | Xt Cdx |
| Stemline Therapeutics INC. | $125.00 | 2025 | Orserdu |
| Adc Therapeutics America, INC. | $125.00 | 2025 | |
| Abbvie INC. | $124.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $121.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.67 | 2024-2025 | Imfinzi, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $116.91 | 2019-2025 | Fruzaqla |
| Advanced Accelerator Applications | $92.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $87.46 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quinten Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.